Skip to content
value.today

Recode Therapeutics, Inc.

🇺🇸 Irving, Texas, USAHealth CareFounded 2015
Total raised
$289 M
3 rounds on record
Latest round
$260 M
Oct 2021
First round on record
Dec 2016
Today
Private
No later event on record

Funding rounds

3 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Recode Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Oct 2021$260 MNo. 3$250 million to $1 billion

Recode Therapeutics, Inc.: Raise no. 3, Oct 2021

Investors in this round

28 investors had bought by the notice of Sep 28, 2023: 28 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$260 M of $290 M offered; $30 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • David S. Lockhart · Executive Officer
  • Shehnaaz Suliman · Executive Officer, Director, Promoter
  • Alan S. Colowick · Director
  • Edward S. Hurwitz · Director
  • Helen S. Kim · Director
  • Kouki S. Harasaki · Director
  • Oleg S. Nodelman · Director
  • Peter A. Thompson · Director
  • Rakhshita S. Dhar · Director
  • Rana S. Al-Hallaq · Director
  • Trisha S. Millican · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Max Barker, Secretary of the Issuer. Source: SEC Form D and 3 amendments, newest notice filed Sep 28, 2023. Read the notice at the SEC.

equitySEC
Mar 2020$28 MNo. 2$10 to $50 million

Recode Therapeutics, Inc.: Raise no. 2, Mar 2020

Investors in this round

9 investors had bought by the notice of Mar 20, 2020: 9 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$28 M of $80 M offered; $53 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
$400,000 (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • David J Lockhart · Executive Officer, Director
  • Edward J Hurwitz · Director
  • Helen J Kim · Director
  • Michael J Torres · Director
  • Peter J Thompson · Director
  • RA J Session II · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by David J. Lockhart, CEO and President. Source: SEC Form D, newest notice filed Mar 20, 2020. Read the notice at the SEC.

equitySEC
Dec 2016$2 MNo. 1$2 to $10 million

Recode Therapeutics, Inc.: Raise no. 1, Dec 2016

Investors in this round

1 investor had bought by the notice of Feb 8, 2019: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $3 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Up to $1 million
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Texas

People named in the notice

  • Arthur E Johnson · Executive Officer, Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Arthur E Johnson, President. Source: SEC Form D and 1 amendment, newest notice filed Feb 8, 2019. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Recode Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Sep 2023).

    SEC Form D · Sep 2023

  • The industry group it chose in its notices: Other Health Care.

    SEC Form D · Sep 2023

That is all the official record says: Recode Therapeutics, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Recode Therapeutics, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 28 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Recode Therapeutics, Inc.
NameRoleNamed in
David S. LockhartExecutive officerSep 2023
Shehnaaz SulimanExecutive officerSep 2023
David J. LockhartExecutive officerJan 2023
Shehnaaz S. SulimanExecutive officerJan 2023
Julia S. EastlandExecutive officerOct 2021
David J LockhartExecutive officerMar 2020
Arthur E JohnsonExecutive officerFeb 2019
Alan S. ColowickDirectorSep 2023
Edward S. HurwitzDirectorSep 2023
Helen S. KimDirectorSep 2023
Kouki S. HarasakiDirectorSep 2023
Oleg S. NodelmanDirectorSep 2023
Peter A. ThompsonDirectorSep 2023
Rakhshita S. DharDirectorSep 2023
Rana S. Al-HallaqDirectorSep 2023
Shehnaaz SulimanDirectorSep 2023
Trisha S. MillicanDirectorSep 2023
Shehnaaz S. SulimanDirectorJan 2023
David J. LockhartDirectorOct 2021
RA S. Session IIDirectorOct 2021
David J LockhartDirectorMar 2020
Edward J HurwitzDirectorMar 2020
Helen J KimDirectorMar 2020
Michael J TorresDirectorMar 2020
Peter J ThompsonDirectorMar 2020
RA J Session IIDirectorMar 2020
Arthur E JohnsonDirectorFeb 2019
Shehnaaz SulimanPromoterSep 2023